Swiss pharmaceutical group Roche agreed to acquire PathAI. PathAI is a U.S.-based specialist in artificial intelligence-powered pathology diagnostics.
The deal aims to strengthen Roche's position in digital pathology by using AI to automate workflows. This technology improves the precision of disease diagnosis.
The acquisition is valued at up to $1.05 billion. Roche will make an upfront payment of $750 million. The agreement includes up to $300 million in additional milestone payments.
The transaction builds upon a partnership between the two companies that began in 2021. Both parties expect the deal to close in the second half of 2026.
Roche will integrate PathAI into its diagnostics division following the acquisition.